Posted inNews and Updates
FDA Chief Calls Out Excessive Markups on Medical Supplies
FDA leadership is scrutinizing unexplained price markups on medical consumables, signaling a potential shift toward greater supply chain transparency.
Posted inNews and Updates
ALS Breakthrough: Coya Therapeutics Hits Enrollment Milestone
Coya Therapeutics hits a major milestone as the 100th patient joins the ALSTARS trial for COYA 302, a promising new approach to treating ALS.
Posted inNews and Updates
Ivonescimab Shows Survival Benefit in EGFR-Mutated NSCLC
New trial data shows ivonescimab significantly improves overall survival in EGFR-mutated NSCLC patients, offering a potential breakthrough in lung cancer.
Posted inNews and Updates
New Drug Shows Promise for Osimertinib-Resistant Lung Cancer
BH-30643 shows a 45% response rate in osimertinib-resistant NSCLC patients. Discover how this new targeted therapy is breaking down cancer drug resistance.
Posted inNews and Updates
Roche’s Lunsumio Combo Shows Promise in Lymphoma Trial
Roche’s Phase III trial finds the Lunsumio combination meets primary endpoints for follicular lymphoma, offering new hope for durable cancer treatment.
Posted inNews and Updates
DOLF Project Advances Onchocerciasis Treatment Trial
The DOLF project enters its final trial stage in Liberia, testing a triple-drug regimen to accelerate the global eradication of river blindness.
Posted inNews and Updates
Arrowhead Reports New Data for Mixed Hyperlipidaemia Drug
Arrowhead Pharmaceuticals reveals promising clinical trial results for its RNAi therapy treating mixed hyperlipidaemia. Discover the potential impact here.
Posted inNews and Updates
Avacta Announces Clinical Proof of Mechanism for AVA6000
Avacta confirms clinical proof of mechanism for AVA6000, a groundbreaking pro-drug designed to reduce chemotherapy side effects using FAP-targeted therapy.
Posted inFitness & Exercise
Avacta Announces Clinical Proof of Mechanism for AVA6000
Avacta confirms clinical proof of mechanism for AVA6000, a groundbreaking pro-drug designed to reduce chemotherapy side effects using FAP-targeted therapy.
Posted inNews and Updates
Arch Biopartners Stock Analysis: Clinical and Fiscal Outlook
Arch Biopartners sees shares dip amid market scrutiny. Discover how clinical trial progress and fiscal runway are impacting the firm's biotech outlook.